Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH3)

NCT03112603 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT03112603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03112603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH3)
Lead sponsor
Incyte Corporation
Phase
Phase 3
Overall status
Completed
Start date
June 29, 2017
Completion date
December 15, 2022
Enrollment
330 (actual)
Sites
191

Conditions

As the registry lists them; a condition with its own page is linked.

graft-versus-host disease (gvhd)